The Details

Take your laboratory to the next level of productivity with Capture^®, a proven IgG specific solid phase technology for antibody screening.

High Accuracy.

• Detect clinically significant antibodies with IgG specific technology - compares to enzyme methods without the added work¹
• Provides high sensitivity for clinically significant antibodies, without the noise of IgM
• Reports describe the use of Werfen products to help mitigate interference with monoclonal antibody therapies^{2, 3}

Easy to Use.

• Save time with ready to use reagents
• No liquid screening cells to manage because antigens are precoated on the microwells
• Less hands-on time with no precision pipetting required
• Simplify training with the same methodology and procedures for all assays

Versatility and Flexibility for Labs of All Sizes.

• A wash step allows for the use of slightly lipemic or hemolyzed samples
• Run a single sample or a full batch
• Manual, semi-automated and fully automated scalable solutions
• Multiple options in automated red blood cell antibody detection

​

Trust Capture for Reliability.

Capture-R Ready-Screen is the method of choice for screening over 90% of the North American blood supply and has been utilized in renowned blood donor centers globally for nearly 40 years.

​​​​​Consistent and Accurate Manufacturing.

• Werfen has a rich supply of donors. Our database of over 10,000 typed donors is utilized to create the best antigen profile on every lot.
• Our donors are phenotyped by two separate laboratories using unique reagents.

1 Funato, Y. (2018, March). Scientific Study on Comparison of Column with Enzyme and Capture without Enzyme. Toyonaka, Japan; Toyonaka Hp.

2 Howard-Menk C, Crane JE, Doshi L, Papari M. HU5F9-G4 Monoclonal Anti-CD47 Therapy: A First Experience with Interference in Antibody Identification. Transfusion 2018; 58 [S2]:177A.​​​​​​​​​​​​​​​

3 De Vooght KMK, Lozano M, Bueno JL, et al. Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary. Vox Sanguinis 2018; 113:492-498.

Product offerings may differ by region, please check with your local Werfen representative for regulatory status in your area.